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Abstract: The intractability of non-small cell lung cancer (NSCLC) to multimodality treatments 
plays a large part in its extremely poor prognosis. Tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) is a promising cytokine for selective induction of apoptosis in cancer 
cells; however, many NSCLC cell lines are resistant to TRAIL-induced apoptosis. The thera-
peutic effect can be restored by treatments combining TRAIL with chemotherapeutic agents. 
Actinomycin D (ActD) can sensitize NSCLC cells to TRAIL-induced apoptosis by upregulation 
of death receptor 4 (DR4) or 5 (DR5). However, the use of ActD has significant drawbacks due 
to the side effects that result from its nonspecific biodistribution in vivo. In addition, the short 
half-life of TRAIL in serum also limits the antitumor effect of treatments combining TRAIL and 
ActD. In this study, we designed a combination treatment of long-circulating TRAIL liposomes 
and ActD liposomes with the aim of resolving these problems. The combination of TRAIL 
liposomes and ActD liposomes had a synergistic cytotoxic effect against A-549 cells. The 
mechanism behind this combination treatment includes both increased expression of DR5 and 
caspase activation. Moreover, systemic administration of the combination of TRAIL liposomes 
and ActD liposomes suppressed both tumor formation and growth of established subcutane-
ous NSCLC xenografts in nude mice, inducing apoptosis without causing significant general 
toxicity. These results provide preclinical proof-of-principle for a novel therapeutic strategy in 
which TRAIL liposomes are safely combined with ActD liposomes.
Keywords: TRAIL, actinomycin D, liposomes, combination treatment, non-small cell lung 
cancer
Introduction
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases of 
lung cancer, which is the leading cause of cancer-related mortality in both men and 
women throughout the world.1 Systemic chemotherapy has been considered the main 
treatment for patients with early-stage NSCLC and part of the multimodal therapeutic 
strategy for advanced-stage NSCLC.1,2 However, limited efficiency has been achieved 
using chemotherapy. For example, the use of cytotoxic chemotherapy is associated with 
a response rate of 20%–35% and a median survival time of 10–12 months in patients 
with advanced NSCLC.3 This may be due to multidrug resistance in NSCLC. Several 
resistance proteins, including P-glycoprotein, lung resistance protein, and multidrug 
resistance-associated protein, have been proven to be simultaneously involved in 
multidrug resistance of NSCLC.4 Therefore, there is a need to develop new anticancer 
drugs and novel regimens capable of killing drug-resistant cells. Activation of the death 
receptor pathway may provide a new modality in NSCLC treatment because of the 
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ability of death receptors to induce apoptosis directly, thus 
bypassing cellular drug resistance.5
A new candidate, tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL), was identified as a powerful activa-
tor of programmed cell death or apoptosis in tumor cells that 
also spared normal cells.6 TRAIL-induced apoptosis starts 
with the binding of TRAIL to its cognate receptors DR4/5. 
This binding leads to the formation of a death-inducing 
signaling complex and subsequent activation of caspase-8. 
Caspase-8 then activates downstream effector caspases, such 
as caspase-3 and caspase-6, ultimately resulting in apoptosis.7 
The selectivity of TRAIL for tumor cells has greatly spurred 
research to explore its potential as an anticancer therapy.6,8,9 
Although TRAIL is capable of inducing apoptosis in tumor 
cells of diverse origin, recent studies have shown that the 
majority of NSCLC lines, such as A-549 and H-522, are 
resistant to the apoptotic effects of TRAIL, suggesting that 
the use of TRAIL alone may be ineffective for NSCLC 
therapy.10
There is increasing evidence that conventional chemo-
therapeutic agents upregulate death receptors in human 
cancer cells. Therefore, it is possible that these conventional 
chemotherapeutic drugs would enhance the cytotoxicity 
of TRAIL. This approach might be useful in killing drug-
resistant cells. Importantly, a number of studies have shown 
that treatments combining TRAIL with chemotherapy have 
synergistic effects in several human tumor types and can 
overcome resistance to either of the agents.10 Actinomycin D 
(ActD), which is known to be a potent cytotoxic drug, can 
sensitize pancreatic cancer and NSCLC cells to TRAIL-
induced apoptosis.11–13 However, the effectiveness of this 
combination therapy on NSCLC xenograft model systems has 
not been reported. Therefore, evaluation of the therapeutic 
efficiency of combined ActD/TRAIL treatment on NSCLC 
xenografts is necessary and feasible.
However, use of ActD has inevitable drawbacks due to 
the side effects that result from its nonspecific biodistribution 
in vivo. In addition, the short half-life of TRAIL in serum14 
could also limit the antitumor effect of combined treatment 
with TRAIL and ActD. In addition, some NSCLC cell lines 
demonstrate cross-resistance to both TRAIL and ActD, 
 making combination therapies less effective.4,10
In recent years, liposomes have garnered attention for 
cancer therapy because of their biocompatibility and versa-
tility of formulation.15 Compared with free antitumor drugs, 
drug-loaded long-circulating liposomes show a long circula-
tion time in plasma, enhanced accumulation in tumor tissues, 
and superior therapeutic activity. Our previous  studies have 
indicated that the combination of TRAIL liposomes and 
 doxorubicin liposomes enhances antitumor effects.16,17 In 
spite of these potential advantages, long-circulating lipo-
somes have not been tested as a carrier for ActD, and the 
clinical application of TRAIL liposomes combined with 
ActD liposomes may result in enhanced antitumor effects.
The objective of the present study was to determine 
whether ActD liposomes augment TRAIL liposome-induced 
apoptosis of A-549, a NSCLC cell line, and to investigate 
the underlying mechanisms by which this combined treat-
ment achieves enhanced elimination of cancer cells. We 
used the A-549 cell line as a multidrug resistant lung tumor 
cell model because of the presence of ATP-binding cassette 
efflux pumps such as P-glycoprotein, multidrug resistance-
associated protein, and breast cancer resistance protein in 
A-549 cells.18
Materials and methods
Materials and animals
ActD was obtained from Life Science Co (Shanghai, 
China). Human recombinant TRAIL was supplied by the 
Shanghai Qiaer Biotechnology Co, Ltd, (Shanghai, China). 
2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride 
(DAPI) and MTT were purchased from Sigma (St Louis, 
MO). Antihuman death receptor 4 (DR4) and 5 (DR5) anti-
bodies, human recombinant DR5/Fc and DR4/Fc chimera 
proteins, monoclonal antihuman TRAILR1-phycoerytherin, 
and monoclonal antihuman TRAILR2-phycoerytherin were 
obtained from R & D Systems Inc (Minneapolis, MN). 
Antibodies to caspase-9, caspase-3, and caspase-8 were 
obtained from Bioworld Technology Inc (Louis Park, MN). 
Egg yolk phosphatidylcholine (EPC) was purchased from QP 
Corporation (Tokyo, Japan). Cholesterol (CHOL) and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy 
(polyethylene glycol)-2000] (DSPE-mPEG-2000) were 
obtained from Avanti Polar Lipids Inc (Alabaster, AL). Fetal 
bovine serum and Roswell Park Memorial Institute (RPMI) 
1640 were ordered from Gibco (Carlsbad, CA). Double-
distilled water was purified using a Millipore Simplicity 
System (Millipore, Bedford, MA). All other materials were 
of analytical grade and used without further purification.
The NSCLC cell line A-549 was obtained from the 
Institute of Biochemistry and Cell Biology at the Shanghai 
Institutes for Biological Sciences of the Chinese Academy of 
Sciences (Shanghai, China). The cells were cultured in RPMI 
1640 supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 10% fetal bovine serum at 37°C in a 
humidified 5% CO
2
 atmosphere.
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BALB/c mice (BK Lab Animal Co Ltd, Shanghai, China) 
were treated according to protocols approved by the Ethics 
Committee of Fudan University.
TRAIL stability study
TRAIL was dissolved in phosphate-buffered solution 
(pH 7.4) at a concentration of 100 µg/mL, and then 3 mL 
of 100 µg/mL TRAIL was divided into samples 1 (1 mL), 
2 (1 mL), and 3 (1 mL). Sample 1 was kept at room tempera-
ture as a control. Sample 2 was incubated in a water bath at 
40°C for one hour, while sample 3 was kept at 50°C for one 
hour. The cytotoxicity of each sample on A-549 cells was 
then investigated using the MTT assay.
Preparation of ActD liposomes
The formulation of ActD liposomes was as follows: 
EPC:CHOL:DSPE-mPEG-2000:ActD = 20:5:5:0.8 (w/w). 
Briefly, ActD (0.8 mg) and lipids with the compositions 
described above were dissolved in 6 mL of chloroform. 
 Following the addition of 4 mL of phosphate-buffered solution 
(pH 7.4), a dry lipid film prepared from the mixture was vor-
texed for 5 minutes and then suspended for 4 hours. The lipo-
somal suspension was then subjected to a sonication procedure 
of 200 W for 20 seconds (intermittent). Large liposomes and 
nonentrapped ActD particles were removed by three passes 
through polycarbonate membrane filters with 0.22 µm pores. 
The ActD liposomes were stored at 4°C until use.
The TRAIL liposomes were prepared as previously 
reported.17 The lipid composition of the TRAIL liposomes 
was as follows: EPC:CHOL:DSPE-mPEG-2000 = 65:15:15 
(w/w). Briefly, lipids with the compositions described above 
(total weight 95 mg) were dissolved in chloroform, dried into 
a thin film in a round bottom flask on a rotary evaporator 
under reduced pressure at 40°C. The dried lipid film was 
rehydrated in 4 mL of 5 mg/ml TRAIL solution adjusted to 
pH 7.4 and 290 osmolarity with NaCl at room temperature, 
sonicated in an ice bath, and then subsequently extruded three 
times through a 0.22 µm pore size polycarbonate filter. The 
resulting liposomes were filtered through sepharose (CL-4B) 
to remove nonentrapped TRAIL.
Characterization of liposomes
Liposome size was determined by dynamic light scattering 
using a zeta potential/particle sizer Nicomp 380 ZLS (Particle 
Sizing Systems, Santa Barbara, CA). In addition, liposomes 
were observed using transmission electron microscopy 
(H-600, Hitachi, Japan) following negative staining with 1% 
sodium phosphotungstate solution for 2 minutes.
The concentration of ActD within the liposomes was 
measured by ultraviolet absorbance at 458 nm (UV-2401PC, 
Shimadzu, Tokyo, Japan). Briefly, 2 mL of the filtered ActD 
liposomes or nonfiltered ActD liposomes was dissolved in 
7 mL ethanol, and the final volume was adjusted to 10 mL 
with ethanol. After vortexing for 10 minutes, this suspen-
sion was filtered with polycarbonate membrane filters with 
0.22 µm pores to remove undissolved materials. The ultra-
violet absorbance of each sample was then measured and 
the concentration of ActD was determined accordingly. 
The loading efficiency was calculated using the following 
equation:
 Loading efficiency (%) = Fi/Ft × 100 (1)
where Fi is the concentration of ActD loaded in the lipo-
somes after their dissolution in ethanol and Ft is the initial 
concentration of ActD.
In contrast, nonentrapped TRAIL was tested using the 
Coomassie Brilliant Blue G-250 binding assay.19 Briefly, 
the nonentrapped TRAIL was collected by passing TRAIL 
liposomes through sepharose; 2.5 mL of Coomassie Brilliant 
Blue G-250 (0.5 mg/mL) was then added to 1 mL of the col-
lected TRAIL solution. A series of concentrations of TRAIL 
(2–80 µg/mL) was used as a control. The ultraviolet A
450
 
and A
590
 of each sample were measured within 20 minutes. 
The concentration of TRAIL was determined by A
590
/A
450.
 
The loading efficiency of TRAIL was calculated using the 
following equation:
 Loading efficiency (%) = (Ft - Fi)/Ft × 100 (2)
where Fi is the concentration of nonentrapped TRAIL after 
the liposomes were passed through the sepharose column 
and Ft is the initial concentration of TRAIL.
The release of TRAIL or ActD from liposomes was 
examined by incubating 1 mL of liposomes in a dialysis bag 
immersed in 20 mL of phosphate-buffered solution (pH 7.4). 
The entire system was stirred at 37°C. The amount of TRAIL 
and ActD released at each time point was determined using 
Coomassie Brilliant Blue G-250 binding and ultraviolet 
analysis, respectively.
Nuclear staining
A-549 cells were placed in six-well culture plates (5 × 105/well) 
and incubated for about 12 hours. The cells were then treated 
for 12 hours with TRAIL liposomes alone (100 ng/mL), ActD 
liposomes alone (1 µg/mL) or both. The culture medium 
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was then removed and cells were washed with phosphate-
buffered solution twice and fixed with 3.7% paraformalde-
hyde in phosphate-buffered solution for 10 minutes at room 
 temperature. Fixed cells were washed three times with phos-
phate-buffered solution and stained with 0.5 µg/mL DAPI 
solution for 15 minutes in the dark at room temperature. 
Finally, cells were observed via fluorescence microscopy 
(Leitz, Germany).
Cytotoxicity assay
Cytotoxicity was evaluated using the MTT survival assay. 
Briefly, A-549 cells were plated at 10,000 cells/well in 
96-well microtiter plates overnight. Cells were then treated 
with 100 µL fresh medium containing ActD liposomes alone, 
TRAIL liposomes alone, or both agents and cultured for 
24 hours. Following an additional 4 hours of culture with 
0.5 mg/mL MTT, samples were analyzed using a microplate 
reader (Multiskan MK3, Thermo Scientific, MA). The effects 
of the treatments were expressed as a percentage of growth 
inhibition using untreated cells as the noninhibited control.
Western blot analysis
Preparation of whole cell protein lysates and Western blot 
analysis were performed as previously described.20,21 In brief, 
whole cell protein lysates were electrophoresed through 
denaturing polyacrylamide slab gels, and the protein bands 
were transferred to a polyvinylidene fluoride membrane. 
The membrane was then probed with primary antibodies to 
caspase-9 (1:1000), caspase-8 (1:1000), caspase-3 (1:1000), 
DR5 (1:1000), DR4 (1:1000), and GAPDH (1:1000) from 
Sigma, St Louis, MO. Primary antibodies were detected using 
goat antimouse or antirabbit horseradish peroxidase-link 
secondary antibodies (1:10,000). After washing, the ECL 
chemical reagents were added to the membrane and chemi-
luminescence was detected by exposure of the membranes to 
Kodak-X-Omat films for 30 seconds to 10 minutes.
Membrane expression of DR4 and DR5
Cells were analyzed for surface expression of DR4 and DR5 
by direct staining with monoclonal antihuman TRAILR1-
phycoerytherin and monoclonal anti-human TRAILR2-
phycoerytherin. Briefly, cells were seeded at 1 × 105 cells/
well in 24-well plates overnight. Cells were then treated 
with fresh medium containing ActD liposomes and fur-
ther cultured for 8 hours. Cells were stained with 0.5 mL 
phosphate-buffered solution containing 1 µg/mL of mono-
clonal antihuman TRAILR1-phycoerytherin or monoclonal 
antihuman TRAILR2-phycoerytherin antibody at 4°C for 
30–45 minutes. After washing with phosphate-buffered 
solution, the expression of DR4 or DR5 was analyzed using 
fluorescence microscopy (Leitz, Germany).
Antitumor activity of ActD and TRAIL 
liposome combination treatment
A-549 cells (2 × 106) were suspended in 0.1 mL phosphate-
buffered solution and injected subcutaneously into the right 
flank of BALB-C strain female nude mice 6–8 weeks of age. 
For the treatment of the established xenografts, the tumors 
were permitted to establish and grow for 20 days (tumor 
volume, 50–100 mm3). After tumor formation, the mice 
were divided into seven treatment groups (five mice/group) 
and received injection of the following treatments via tail 
vein: control (pH 7.4 phosphate-buffered solution); TRAIL 
0.6 mg/kg; ActD 0.06 mg/kg; TRAIL 0.6 mg/kg + ActD 
0.06 mg/kg, pH 7.4 phosphate-buffered solution; TRAIL 
liposomes 0.6 mg/kg; ActD liposomes 0.06 mg/kg; TRAIL 
liposomes 0.6 mg/kg + ActD liposomes 0.06 mg/kg. The 
administration of drugs was carried out daily for 12 days. 
Tumor size was measured with calipers every day. Tumor 
volume was calculated using the following formula: 
1/2 × (larger diameter) × (smaller diameter).2 Systemic 
toxicity of the treatments was assessed by changes in mouse 
body weight.
Statistical analysis
Statistical evaluations of data were performed using the 
unpaired Student’s t-test and one-way analysis of variance. 
Data were expressed as the mean ± standard deviation. 
P , 0.05 was considered to be significant.
Results
TRAIL stability study
Although the sonication of liposomes was performed in an ice 
bath, it is difficult to avoid heat buildup in a liposomal suspen-
sion. Because the activity of bioactive proteins can be easily 
damaged by heat, we tested the susceptibility of TRAIL to 
heat. As shown in Figure 1, heat treatment of TRAIL at 40°C 
or 50°C for one hour had only a slight influence on TRAIL 
bioactivity, suggesting that the bioactivity of TRAIL may 
not be damaged by the sonication. In addition, the sonication 
procedure did not significantly damage the TRAIL potent 
(data not shown). These results indicated that the sonica-
tion procedure can be utilized in the preparation of TRAIL 
liposomes. To the best of our knowledge, a stability study 
of this type has not been previously reported.
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Figure 1 Effect of heat treatment on cytotoxicity of TRAIL to A-549 cells. Because A-549 cells are resistant to TRAIL, we added 1 µg/mL of actinomycin D to each 
concentration of TRAIL as a sensitizer. 
Abbreviation: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
Table 1 Physical properties of the liposomal formulations
TRAIL liposomes ActD liposomes
Loading efficiency (%)  10.4 ± 3.9  92.0 ± 4.51
Particle size (nm) 115.6 ± 25.4 110.5 ± 45.3
Cumulative release  
at 24 hours (%)
 71.2 ± 4.3  62.9 ± 5.7
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; 
ActD, actinomycin D.
Figure 2 Transmission electron micrographs of liposomes. TRAIL liposomes (left), 
ActD liposomes (right).
Note: Bar = 100 nm. 
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; 
ActD, actinomycin D.
Characteristics of liposomes
The physical properties of liposomes are listed in Table 1. 
Dynamic light scattering results demonstrated that volume-
based diameters of TRAIL liposomes and ActD liposomes 
were around 110 nm, which is especially suitable for accumu-
lation in tumor tissue due to enhanced permeation and reten-
tion.22 Importantly, the in vitro release results for the TRAIL 
liposomes and ActD liposomes showed that the liposomes can 
sustain ActD and TRAIL release, suggesting the possibility of 
a prolonged circulation time for both drugs. We also examined 
the shape and size of these liposomes under a transmission 
electron microscope (Figure 2). Most TRAIL and ActD lipo-
somes were spherical and had a regular shape.
Cytotoxicity assay
For qualitative assessment of apoptosis induced by TRAIL 
liposomes alone, ActD liposomes alone, or both agents, 
we analyzed chromatin condensation and apoptotic  bodies. 
As shown in Figure 3A, treatment with TRAIL lipo-
somes (100 ng/mL) alone for 12 hours did not induce any 
 morphological features or apoptotic bodies indicative of cell 
death. Treatment with ActD liposomes (1.0 µg/mL) alone 
induced only a slight increase in such morphological changes 
and apoptotic bodies. In contrast, after combined treatment 
with TRAIL liposomes and ActD liposomes, appearance of 
apoptotic bodies was observed in A-549 cells. After washing 
with phosphate-buffered solution and staining with DAPI, the 
presence of apoptotic bodies and remarkably lower growth 
density in cells treated with the combination treatment was 
apparent (Figure 3B). This indicates that numerous dead 
tumor cells produced by the combination treatment were 
washed away by phosphate-buffered solution. These results 
demonstrate that ActD liposomes significantly enhance apop-
tosis induced by TRAIL liposomes in A-549 cells.
To investigate further the cytotoxic effects of TRAIL lipo-
somes and/or ActD liposomes, we treated A-549 cells with 
the indicated agents and subjected them to the MTT assay. 
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Figure 3 Induction of apoptosis in A-549 cells by TRAIL liposomes and/or ActD liposomes. (A) Bar = 250 µm. (B) Bar = 250 µm. 
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ActD, actinomycin D; LPs, liposomes.
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Figure 4 (A) Effect of TRAIL liposomes and/or ActD liposomes on growth inhibition of A-549 cells. (B) Cell inhibition induced by forward or reverse sequential treatment 
of TRAIL liposomes and ActD liposomes: 1, ActD liposome treatment for 24 hours; 2, TRAIL liposome treatment for 24 hours; 3, ActD liposome treatment for 8 hours → 
TRAIL liposome treatment for 16 hours; 4, TRAIL liposome treatment for 16 hours → ActD liposome treatment for 8 hours.
Note: **P , 0.01.
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ActD, actinomycin D; LPs, liposomes.
As shown in Figure 4A, neither TRAIL liposomes nor 
ActD liposomes can significantly inhibit cell growth as 
single agents; however, combined treatment with TRAIL 
liposomes and ActD liposomes resulted in a sharp increase 
in cell inhibition. This result is consistent with results 
reported elsewhere.10 Importantly, when A-549 cells were 
treated with TRAIL liposomes (1.4–1000 ng/mL) and ActD 
(1.4–1000 ng/mL) at a fixed ratio (1:1, w/w) for 24 hours, 
the inhibition of cells significantly increased compared with 
single treatment at each concentration point, confirming that 
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cotreatment with TRAIL liposomes and ActD liposomes is 
effective in inducing cell death. Similar results were also 
found in the combined treatment with free TRAIL and ActD 
for 24 hours in the same cell line.
Because A-549 cells are highly resistant to TRAIL-
 induced apoptosis, we next sought to test whether 
A-549 cells can be inhibited by pretreatment with ActD 
liposomes before treatment with TRAIL liposomes. 
Interestingly, if A-549 cells were pretreated with ActD 
liposomes alone for 8 hours followed by treatment with 
TRAIL liposomes for an additional 16 hours, effective 
cell inhibition was also observed (Figure 4B). To examine 
this synergistic interaction, the reverse sequence of drug 
exposure was used, where cells were pretreated with TRAIL 
liposomes for 16 hours, followed by treatment with ActD 
liposomes for an additional 8 hours. This reverse sequence 
of drug exposure resulted in significantly less cell inhibition 
than the sequential treatment of cells with ActD liposomes 
followed by TRAIL liposomes. Taken together, these results 
indicate that sequential treatment with ActD liposomes 
followed by TRAIL liposomes or synchronous treatment 
of ActD liposomes and TRAIL liposomes can be used to 
kill A-549 cells.
ActD liposomes induce upregulation  
of TRAIL receptor DR4 and DR5
It has been previously established that TRAIL induces 
apoptosis through binding to cell receptors. Several TRAIL 
receptors including DR4, DR5, decoy receptor 1 (DcR1), 
2 (DcR2), and osteoprotegerin have been identified to date. 
Both DR4 and DR5 contain a conserved death domain motif 
and transduce TRAIL-mediated death signals to the intracel-
lular apoptotic machinery. Unlike DR4 and DR5, DcR1 lacks 
an intracellular domain, while DcR2 has a truncated death 
domain. Thus, these two receptors act as decoy receptors 
that antagonize TRAIL-induced apoptosis by competing 
for ligand binding.23 Several mechanisms accounting for the 
blocking of TRAIL-induced apoptosis have been reported 
in individual cancer cell lines, including the simultaneous 
expression of decoy receptors,24 overexpression of anti-
apoptotic molecules,25 and loss of caspase-8 expression.26 
A number of studies have shown that anticancer drugs can 
induce DR5 to sensitize cancer cells to TRAIL.27–30 It has also 
been shown that DR4 can be transcriptionally induced by 
chemotherapeutic drugs.31 However, another study showed 
that sensitization can occur without increased TRAIL recep-
tor expression.32 Regardless of total DR4 and DR5 protein 
levels, their absence on the cell surface is sufficient to account 
for the failure to form a TRAIL death-inducing signaling 
complex and later steps in apoptosis.
In light of the studies cited above, it is important to know 
whether ActD liposome treatment leads to regulation of DR4 
and DR5 expression on the cell surface. We therefore evalu-
ated TRAIL receptor expression on the surface of A-549 cells 
at 4, 8, and 12 hours after treatment with ActD liposomes. 
Western blot analysis showed that the basal level of expres-
sion of both DR4 and DR5 increased significantly after 
treatment with ActD liposomes (Figure 5A). The increased 
expression of DR4 and DR5 in A-549 cells may be at least 
one of the reasons for the enhanced cytotoxicity of TRAIL 
liposomes and ActD liposome combination treatment.
DR4
0 h 4 h 8 h 12 h
DR5
GDAPH
DR4 DR5
DR4 DR5
A
B
C
Figure 5 (A) Effects of actinomycin D liposomes on DR4 and DR5 expression. 
A-549 cells were treated with actinomycin D liposomes (0.125 µg/mL) for 4, 8, or 
12 hours, respectively. Cell lysates were examined by Western blot. (B) Fluorescence 
micrographs of DR4 and DR5 expression on untreated A-549 cells. (C) Fluorescence 
micrographs of increased DR4 and DR5 expression on A-549 cells induced by 
actinomycin D liposomes.
Note: Bar = 125 µm.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1455
TRAIL and actinomycin D liposomes
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
12
8.
19
7.
91
 o
n 
20
-N
ov
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2012:7
The DR4 and DR5 upregulation induced by ActD lipo-
somes and subsequent enhancement of TRAIL-mediated 
cytotoxicity in A-549 cells may correlate with p53 status. 
p53 acts as a transcription factor and induces apoptosis by 
increasing gene expression of DR4 and DR5, resulting in 
upregulation of DR4 and DR5 protein synthesis.28,33,34 Cells 
treated with ActD liposomes expressed higher levels of both 
DR4 and DR5 compared with untreated cells (Figure 5B 
and C). In addition, the DR4 and DR5 were distributed 
not only on the cell surface but also in the cytoplasm. It is 
possible that ActD liposomes induce the redistribution 
of DR4 and DR5 to lipid rafts at the plasma membrane, 
favoring their aggregation.35 Although mRNA expression 
of both DR4 and DR5 is present in many cancer cells, there 
is no correlation between receptor expression levels and 
the sensitivity of tumors to TRAIL. Recent studies have 
suggested that the mRNA expression of TRAIL receptors 
does not necessarily reflect their functional levels,36 so we 
only investigated the expression of DR4 and DR5 proteins 
in A-549 cells.
Contribution of DR4 and DR5  
to apoptotic signaling
To investigate the relative contribution of DR4 or DR5 to the 
transduction of the apoptotic signal in sensitive A-549 cells, 
we selectively blocked each of the receptors with the cor-
responding chimeras (DR4/Fc and DR5/Fc, respectively). 
As shown in Figures 6 and 7, only the DR5/Fc chimera 
abolishes the combined effect of ActD liposomes and TRAIL 
liposomes, indicating that the sensitization to apoptosis 
induced by TRAIL liposomes is mediated by one but not 
both upregulated receptors in A-549 cells.
TRAIL + ActD liposomes enhance  
cytotoxicity via caspase activation  
in A-549 cells
Cell apoptosis is primarily induced by two signaling pathways, 
the intrinsic mitochondria-mediated pathway and the extrin-
sic death receptor-induced pathway, and cross-talk between 
these pathways is mediated by the proapoptotic protein, Bid.29 
Steps in the intrinsic pathway include cytochrome c release 
from mitochondria and caspase 9 activation, followed by 
activation of effector caspases, including caspase 3. Steps in 
the extrinsic pathway include Fas-associated death domain-
dependent recruitment and activation of caspase 8, followed 
by activation of the same effector caspases involved in the 
intrinsic pathway.29 In previous studies, we determined that 
DR5 upregulation plays a critical role in the sensitization of 
A-549 cells mediated by ActD liposomes to TRAIL- induced 
apoptosis. Next, we examined whether this sensitizing effect 
was associated with activation of caspase.
Western blot results indicated that TRAIL liposomes 
induced nearly no cleavage of caspase-3 or caspase-9, and 
only slight cleavage of caspase-8 (Figure 8). In contrast, ActD 
liposomes stimulated detectable processing of caspase-9, 
whereas the combination treatment induced substantially 
greater cleavage of caspase-8, caspase-9, and caspase-3, 
therefore resulting in appearance of more active subunits 
of caspase-3, caspase-8, and caspase-9. These observations 
suggest that both the intrinsic mitochondria-mediated path-
way and the extrinsic death receptor-induced pathway are 
involved in the combined treatment.
TRAIL-LPs
ActD-LPs
DR4/Fc
DR5/Fc
+
+
−
−
+
+
+
−
+
+
−
+
A
B
Figure 6 Qualitative assessment of apoptosis induced by TRAIL liposomes, ActD 
liposomes or both agents. (A) Bar = 250 µm. (B) Bar = 250 µm. 
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; 
ActD, actinomycin D; LPs, liposomes.
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Figure 7 ActD liposomes enhance TRAIL liposome-induced cell inhibition through 
upregulation of DR5. A-549 cells were treated with ActD liposomes (1 µg/mL) 
and TRAIL liposomes (100 ng/mL) in the presence or absence of DR4/Fc chimera 
(1000 ng/mL) or DR5/Fc chimera (1000 ng/mL). 
Notes: **P , 0.01. Cell inhibition was tested using the MTT assay. 
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; 
ActD, actinomycin D; LPs, liposomes.
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Treatment of A-549 tumor xenografts 
with TRAIL + ActD liposomes causes 
growth suppression
We next tested the antitumor efficiency of the combination 
treatment in vivo. Mice bearing subcutaneous A-549 tumor 
xenografts were treated systemically with indicated agents 
as described in the Materials and methods sections. The final 
tumor volume of mice treated with the combination of TRAIL 
liposomes and ActD liposomes was notably reduced. Further-
more, the tumor growth curve showed that tumor growth was 
delayed most prominently in the group treated with TRAIL 
liposomes and ActD liposomes (Figure 9A). The final weight 
of tumor nodules in the group treated with TRAIL liposomes 
and ActD liposomes was 392.2 ± 119.3 g (Table 2), which 
was significantly lower than in the other groups. We were also 
surprised to find no significant tumor inhibition in the other 
groups, indicating the superiority of liposomal combination 
treatment. In this study, body weight change was used as a 
marker of the safety of the treatment. As shown in Figure 9B, 
the body weight of mice treated with ActD, ActD liposomes, 
ActD + TRAIL and ActD  liposomes + TRAIL liposomes 
recovered after cessation of drug treatment. In contrast, 
the body weight of mice administered phosphate-buffered 
solution, TRAIL, and TRAIL liposomes gradually increased 
during the whole treatment period, again demonstrating the 
minor side effects of TRAIL used alone.
Discussion
The high frequency of intrinsically TRAIL-resistant 
NSCLC cell lines requires strategies to sensitize tumors for 
TRAIL-induced apoptosis. Fortunately, the combined use of 
TRAIL with chemotherapeutic drugs provides an option for 
 increasing antitumor activity in NSCLC models. The efficacy 
of combined treatment with TRAIL and chemotherapy on 
NSCLC has been demonstrated in a number of studies.10 
However, the short half-life of TRAIL results in reduced 
antitumor effects in vivo, which leads to the requirement for 
larger amounts of TRAIL in clinical trials. Recent studies 
have reported unanticipated side effects of TRAIL, including 
proangiogenic-enhanced endothelial cell proliferation, migra-
tion, and cytoskeletal reorganization.37,38 In addition, a chief 
concern with conventional chemotherapies is the inevitable 
side effects from the nonspecific biodistribution of chemo-
therapeutic drugs. However, to date a strategy to improve 
on the challenges posed by combination treatment has not 
been reported in the published scientific literature. Here, we 
used long-circulating liposomes as carriers to encapsulate 
ActD and TRAIL with the aim of improving the therapeutic 
efficiency and reducing the side effects. Our results indicate 
that the combination of ActD liposomes with TRAIL lipo-
somes has a better therapeutic effect against NSCLC than 
free TRAIL and ActD combination treatment.
Long-circulating liposomes which are sterically stabilized 
with surface-coupled polyethylene glycol and have approxi-
mately a 100 nm mean diameter can have an enhanced lifespan 
in the circulation which is also conferred to their entrapped 
therapeutic agents.39 In recent years, the development of 
long-circulating liposomes has made it possible to prolong 
the circulation time of anticancer drugs, target tumors, and 
Procaspase-3
Procaspase-8
Procaspase-9
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46 KD
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ActD-LPs
−
−
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+
+
+
Figure 8 Effects of ActD liposomes or/and TRAIL liposomes on caspase activation. 
A-549 cells were treated with ActD liposomes (1 µg/mL) and/or TRAIL liposomes 
(100 ng/mL) for 12 hours. 
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; 
ActD, actinomycin D; LPs, liposomes.
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Figure 9 (A) In vivo anticancer efficacy of different treatments in A-549 tumor 
xenografts and (B) change in body weight as a function of time in subcutaneous 
A-549 xenograft-bearing mice. 
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; 
ActD, actinomycin D; LPs, liposomes.
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reduce side effects. For example, doxorubicin is an area-
under-the-curve-dependent anticancer agent and is often used 
for liposomal targeting to tumors. After encapsulation in long-
circulating liposomes, liposomal doxorubicin can be delivered 
to the extracellular space of tumor tissues. The doxorubicin 
released in the extracellular space of tumors enhance its effec-
tiveness and substantially increase the therapeutic index.22 In 
this study, the synchronous accumulation of ActD liposomes 
and TRAIL liposomes in tumors and subsequent drug release 
in the extracellular space of tumors had a remarkable syner-
gistic effect on the elimination of A-549 cells.
One phenomenon that should be noted is that no signifi-
cant tumor inhibition was observed in mice treated with the 
combination of free TRAIL and ActD (Table 2). As reported 
elsewhere, in order to induce DR4 or DR5 in tumor tissue, 
chemotherapeutic drugs were usually injected 24 hours prior 
to administration of TRAIL.5,40,41 However, even with the 
daily systemic injection of the combination of TRAIL and 
ActD for 12 days, no promising antitumor efficiency was 
observed in mice. One plausible explanation for this may be 
that the short half-life of TRAIL allows insufficient time to 
kill A-549 cells. It is also possible that ActD could not reach 
a therapeutic concentration in tumor tissues. These results 
again demonstrate the advantages of liposomes as drug car-
riers in cancer therapy.
TRAIL seems to require DR5 for maximal killing of 
A-549 cells. This observation is consistent with previous 
reports showing that DR5 plays a key role in inducing apop-
tosis in various types of cancer cells.21,33,42 Based on these 
results, DR5 has been the primary target for development 
of antibody therapies. There are currently five anti-DR5 
antibody products, compared with one anti-DR4 product, in 
clinical trials.36 The potential advantage of the DR5 antibody 
is specific binding to the target receptor: the antibodies bind 
selectively and with high affinity to their cognate receptor.43 
In addition, the half-life of DR5, approximately 18–21 days, 
is longer than that of TRAIL. However, the wide distribution 
of DR5 in other tissues and lower accumulation of DR5 at the 
tumor site limits its efficiency. Therefore, we used liposomes 
as a carrier to encapsulate TRAIL.
TRAIL-induced apoptosis uses the mitochondria-
 mediated pathway. As we know, cross-talk between the 
death receptor and mitochondrial pathway is mediated by 
Bid. The cleavage of Bid activates the proapoptotic  members, 
Bax and Bak, resulting in release of cytochrome c from 
the  mitochondria.10 In contrast, Bcl-2 and Bcl-XL inhibit 
chemotherapy or TRAIL-induced apoptosis by blocking 
cytochrome c release.44 A-549 cells are resistant to TRAIL, 
and this may indicate that the activation of caspase-8 in 
A-549 cells by TRAIL alone is not sufficient to activate 
downstream caspase and consequently induce apoptosis. 
However, when A-549 cells were treated with the combina-
tion treatment of ActD liposomes and TRAIL liposomes, 
mitochondria appear to amplify the apoptotic signals, leading 
to more activation of caspase-9. Caspase-9, in turn, activates 
downstream caspases and the cleavage of apoptotic substrates 
that mediate dismantling of the cell, leading to more cleavage 
of caspase-3 into active submits.5
In summary, we have developed a strategy that combines 
ActD liposomes with TRAIL liposomes for the treatment of 
NSCLC. We have shown that ActD liposomes act synergisti-
cally with TRAIL liposomes in inducing apoptosis in the 
A-549 NSCLC cell line compared with treatment using ActD 
liposomes or TRAIL liposomes alone. The enhanced apoptosis 
is due to upregulation of DR5 induced by ActD liposomes in 
A-549 cells. These studies provide a foundation for the devel-
opment of combined treatment regimens that would enhance 
the apoptotic response to TRAIL in cancer patients.
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Table 2 Final tumor weight (mg) of each mouse treated with different formulations
1 2 3 4 5 Average SD P Inhibition (%)
Control 1371 1051 842 879 335 895.6 376.7 – –
TRAIL 1003 951 940 273 293 692.0 374.2 0.05 –
ActD 871 718 800 574 655 723.6 116.9 0.05 –
TRAIL + ActD 834 591 778 293 503 599.8 218.0 0.05 –
TRAIL-LPs 1205 984 751 590 381 782.2 323.4 0.05 –
ActD-LPs 687 737 690 227 232 514.6 261.0 0.05 –
TRAIL-LPs + ActD-LPs 525 423 474 242 297 392.2 119.3 ,0.05 56.2
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ActD, actinomycin D; LPs, liposomes; SD, standard deviation.
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